TX-SLYNC.IO
6.4.2021 09:07:06 CEST | Business Wire | Press release
Slync.io, the innovator behind Logistics Orchestration®, the easy-to-use SaaS platform bringing together logistics processes, data, and systems for global service providers and shippers, announced today the appointment of Paul Pessutti, a software and logistics industry veteran, as its new Executive Vice President & Chief Revenue Officer. This hire comes after Slync.io’s recent Series B funding round of $60 million earlier this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005371/en/
Pessutti brings over 25 years of experience to Slync.io that is focused on achieving customer outcomes, solving difficult business challenges and driving industry innovation. At Slync.io, Pessutti is responsible for setting and executing the company’s global go-to-market strategy and will lead the marketing, sales, and professional services teams in order to scale the organization and solidify its position as a market leader.
Pessutti comes to Slync.io having served as Senior Vice President and General Manager at SAP where he was responsible for the global travel and transportation business and DXC Technology where he led a team of 8,000 people across 70 countries. Pessutti has also held senior leadership roles at GT Nexus, Open Harbor and Maersk.
“As Slync.io continues to grow, the CRO is a critical role for us. Paul’s extensive industry experience, deep enterprise software knowledge, and history of creating value for customers makes him the perfect fit for our team,” said Chris Kirchner, CEO, Chairman and Co-Founder of Slync.io. “I couldn’t be happier that Paul chose to join Slync.io and I’m confident our customers around the world will love working with him.”
“I am excited to join Slync.io at such a pivotal time for the company, where we are hyper-focused on growth and innovation,” said Pessutti. “Slync.io has demonstrated a clear vision for the future and an unmatched commitment to delivering customer value and outcomes through the deep industry expertise residing within our teams. I am thrilled and eager to embark on Slync’s promising next chapter.”
About Slync.io
Slync.io is a SaaS operating platform for global shippers and logistics service providers that delivers higher productivity and process efficiency through intelligent automation. Logistics Orchestration® is an end-to-end service offering that revolutionizes costly back-office processes in global logistics operations. Slync.io connects disparate systems, ingests structured and unstructured datasets, orchestrates teams, and automates processes seamlessly together delivering unprecedented levels of efficiency for logisticians. Get connected, visit www.slync.io or follow us on LinkedIn , Twitter , Instagram , and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005371/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom